FY2017 EPS Estimates for ACADIA Pharmaceuticals Inc. (ACAD) Lifted by Leerink Swann
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at Leerink Swann increased their FY2017 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Tuesday. Leerink Swann analyst P. Matteis now expects that the biopharmaceutical company will post earnings of ($2.38) per share for the year, up from their previous forecast of ($2.53). Leerink Swann has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for ACADIA Pharmaceuticals’ Q4 2017 earnings at ($0.57) EPS, Q2 2018 earnings at ($0.50) EPS, Q3 2018 earnings at ($0.45) EPS, Q4 2018 earnings at ($0.41) EPS, FY2018 earnings at ($1.92) EPS, FY2019 earnings at ($1.49) EPS and FY2020 earnings at ($0.35) EPS.
Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday. Piper Jaffray Companies set a $54.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co set a $50.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 5th. JMP Securities upped their target price on shares of ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, October 5th. Finally, ValuEngine upgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $47.73.
Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at $28.60 on Friday. ACADIA Pharmaceuticals has a fifty-two week low of $24.31 and a fifty-two week high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The company had revenue of $35.58 million for the quarter, compared to analyst estimates of $32.03 million. During the same quarter in the prior year, the business posted ($0.61) EPS. The firm’s revenue was up 571.3% compared to the same quarter last year.
Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of ACADIA Pharmaceuticals by 0.5% during the 2nd quarter. FMR LLC now owns 18,306,966 shares of the biopharmaceutical company’s stock valued at $510,582,000 after acquiring an additional 95,823 shares during the period. Vanguard Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 7,604,605 shares of the biopharmaceutical company’s stock valued at $212,093,000 after acquiring an additional 134,820 shares during the period. BlackRock Inc. grew its position in shares of ACADIA Pharmaceuticals by 2.9% during the 2nd quarter. BlackRock Inc. now owns 5,590,706 shares of the biopharmaceutical company’s stock valued at $155,925,000 after acquiring an additional 157,497 shares during the period. State Street Corp grew its position in shares of ACADIA Pharmaceuticals by 15.8% during the 2nd quarter. State Street Corp now owns 3,748,468 shares of the biopharmaceutical company’s stock valued at $104,551,000 after acquiring an additional 510,670 shares during the period. Finally, Janus Henderson Group PLC bought a new position in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at approximately $102,152,000. 97.01% of the stock is owned by hedge funds and other institutional investors.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 26,507 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $34.87, for a total value of $924,299.09. Following the completion of the sale, the executive vice president now directly owns 94,163 shares of the company’s stock, valued at approximately $3,283,463.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 22.25% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.